Home » Viragen Files to Expand Cancer Approval for Multiferon in Sweden
Viragen Files to Expand Cancer Approval for Multiferon in Sweden
Viragen and its majority-owned subsidiary, Viragen International, have announced that an application has been filed with the Swedish regulatory authorities seeking to expand the approval for Multiferon to include the first-line adjuvant treatment of high-risk malignant melanoma, following dacarbazine after surgical removal of tumors.
This submission represents the initial step of the company's plans to seek broader European approvals for Multiferon.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
11Jul
-
18Jul
-
21Oct